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The Adherence Scale in Chronic 
Diseases (ASCD). The power of 
knowledge: the key to successful patient 
— health care provider cooperation
ABSTRACT
Introduction. Patients’ adherence to long-term therapies is low. It translates into reduced quality of life 
and significant deterioration of health economics. Identification of potential barriers of medication-related 
adherence is a starting point allowing implementation of more advanced interventions directed to adher-
ence improvement.
Aim. The purpose of our study was to create and validate a simple instrument used to assess patients’ 
adherence to recommended medications.
Material and methods. The Adherence Scale in Chronic Diseases is a self-reported questionnaire with 
8 items and with proposed 5 sets of answers. The total score in the Adherence Scale in Chronic Diseases 
ranges from 0 to 32 points. Three levels of adherence were considered (low: scores of 0 to 20; medium 
21 to 25; high > 26). The validation of the questionnaire was conducted in accordance with the validation 
procedure. Assessment of the internal consistency was performed using a-Cronbach coefficient. In order 
to conduct the factor analysis, we assessed: the determinant of correlation matrix, Kaiser-Mayer-Olkin 
(K-M-O) statistic and the Bartlett’s test of sphericity. Factor analysis was conducted using principal com-
ponent analysis with Oblimin rotation. The Kaiser criterion and scree plot were used in order to determine 
components of the questionnaire. Adherence levels were determined based on the percentiles. 
Results. Grand total of 413 patients with a cardiovascular disease were included in the study. The reliability 
and homogeneity of the questionnaire were confirmed by a-Cronbach coefficient (0.739). Factor analysis 
showed that in this questionnaire we can extract two components. The analysis of factor loadings indicated 
excluding item 2 from the questionnaire. After exclusion of the mentioned item, we repeated the validation 
procedure. For such a new dataset, according to the Kaiser criterion, only one component was extracted.
Conclusions. The Adherence Scale in Chronic Diseases is a practical, reliable, consistent and well validated 
instrument for identifying specific obstacles to medication adherence. Its simplicity causes that it can be 
successfully applied in daily practice by health care professionals. Our survey has the potential to improve 
patient — health care professional communication and relationship.
Key words: adherence, barriers of adherence, compliance, medication, self-report scale, patient education, 
persistent therapy
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Introduction
Over the last centuries, there was a remarkable 
progress achieved in medicine and pharmacology. The 
discovery of antibiotics, antivirals, vaccines, antihyper-
tensive drugs, antiplatelet and antithrombotic medica-
tions, new surgical techniques as well as percutaneous 
methods of invasive treatment of many diseases have 
led to a significant improvement in survival of people. 
However, current morbidity and mortality rates do not 
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allow us to celebrate a complete success. In everyday 
practice health care professionals face a dilemma: why, 
despite our effort, so many patients do not respond 
to provided therapies appropriately? Sometimes we 
tailor the therapy accordingly to an individual patient to 
achieve the best result, but even then instead of reward 
we get frustration. Implementation of new methods and 
therapeutic strategies is extremely important, but every 
time we have to take a step backwards we are obliged 
to look closer at our relation with a patient. Does the 
patient know why we recommend a specific therapy? 
Why is it so important to follow it consistently? Does the 
patient realize the consequences of non-adherence? 
Sometimes non-adherence to therapies might not only 
be dangerous but even lethal. 
Starting from Hippocrates [1] doctors pay special 
attention to patients who are at risk of not following 
their recommendations. A phenomenon describing 
the above mentioned situation is called adherence. 
Throughout the years, the definition of adherence 
evolved [2–4]. Currently adherence to medications is 
defined as a process by which patients take their med-
ications as prescribed by health care professionals [2]. 
There are three components of adherence: initiation, 
implementation and discontinuation. Initiation is defined 
as the starting point of the therapy — when a patient 
takes the first dose of a prescribed medication. Imple-
mentation is the extent to which patient’s actual dosing 
corresponds to the prescribed dosing regimen, from 
initiation until the last dose, whereas the discontinua-
tion occurs when a patient stops taking the prescribed 
medication, for whatever reason(s) [2]. 
In the literature, there are many determinants 
defined as responsible for non-adherence [5–7]. 
In general, they can be grouped into following 
sets: socio-economic-related factors, healthcare 
team- and system-related factors, condition-related 
factors, therapy-related factors, and patient-related 
factors [7]. Nevertheless, still many patients escape 
our attention imperceptibly. In developed countries 
adherence to long term therapy for chronic illnesses 
averages 50%, while in developing countries the rates 
are even lower [8]. Poor adherence to long-term 
therapies reduces the effectiveness of treatment 
making it a critical issue in population health in 
terms of quality of life and of health economics [8]. 
Interventions aimed at improving adherence should 
provide a significant positive return on investment 
through primary prevention and secondary preven-
tion of adverse health outcomes [8]. 
Hence the need for an instrument allowing us to 
identify immediately the group of patients potentially 
endangered to be non-adherent to the ordered ther-
apy. The tool must be as simple as possible because 
complex and time consuming instruments will not be 
applied in everyday practice, simply because of the 
limited time for the patient during the stay in the clinic. 
The purpose of our study was to create and validate 
a simple instrument used to assess patients’ adherence 
to recommended medications. Furthermore, thanks to 
a proper set of questions in the survey we want to de-
termine the most common reasons of non-adherence. 
Material and methods
Study group
The study was conducted in the Cardiology Depart-
ment of the Antoni Jurasz University Hospital No. 1 in 
Bydgoszcz and in the Cardiology Outpatient Clinic of the 
Antoni Jurasz University Hospital in Bydgoszcz from May 
2015 to December 2015. The study was approved by the 
Local Bioethical Committee of the Nicolaus Copernicus 
University, Ludwik Rydygier Collegium Medicum in Byd-
goszcz (study approval reference number KB 478/2015).
Survey 
The Adherence Scale in Chronic Diseases was 
designed to facilitate identification of mechanisms 
determining adherence in adult patients with chronic 
illnesses as well as reflect the actual implementation of 
the treatment plan in terms of provided pharmacother-
apy. It is a self-reported questionnaire with 8 questions 
and with proposed 5 sets of answers. All the questions 
refer to determinants of adherence associated with 
behavior and  determinants that can indirectly influence 
the adherence and are related to situations and convic-
tions (Tab. 1). The total score on the Adherence Scale 
in Chronic Diseases can range from 0 to 32 points, with 
scores < 24, 24 to 28 and > 29 reflecting low, medium 
and high adherence respectively.
Statistical analysis
Statistical analyses were conducted using IBM SPSS 
Statistic version 23.0. All statistical tests were performed 
on the significance level a = 0.05. The validation of the 
survey was conducted in accordance with the validation 
procedure. We assessed the internal consistency using 
a-Cronbach coefficient. In order to conduct the factor 
analysis, we assessed: the determinant of correlation 
matrix, Kaiser-Mayer-Olkin (K-M-O) statistic and the 
Bartlett’s test of sphericity. According to the literature, 
the sample size of 413 responders can produce correct 
fractional structure [9]. Factor analysis was conducted 
using principal component analysis with Oblimin rota-
tion. The Kaiser criterion and scree plot were used in 
order to determine components of the questionnaire. 
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Table 1. The Adherence Scale in Chronic Diseases
1. Do you always remember to take all your medications according to your doctor’s instructions? 
A. Always. 
B. Almost always. 
C. Sometimes. 
D. Hardly ever. 
E. Never.
2. Do you find purchasing of the medications prescribed by your doctor a significant financial burden? 
A. No, it is insignificant. 
B. It is burdensome, but acceptable. 
C. It is financially cumbersome, but with some effort I can still afford to buy all my medications. 
D. Occasionally I cannot afford to buy all my medications. 
E. Frequently I cannot afford to buy all my medications.
3. Do you happen to change the dosing of your medications without prior consultation with your doctor? 
A. Never. 
B. Only occasionally. 
C. Sometimes. 
D. Frequently. 
E. I do not adhere to my doctor’s recommendations at all.
4. Do you adjust the dosing of your medications according to how you feel? 
A. No, I strictly follow the prescribed dosing, no matter how I feel. 
B. Yes, I reduce the dosage of some medications when I feel good. 
C. Yes, I skip doses of some medications when I feel good. 
D. Yes, I temporarily discontinue some medications when I feel good. 
E. Yes, I discontinue all medications when I feel good.
5. On the appearance of medication-related side effects (e.g. stomach pain, liver pain, rash, lack of appetite, 
oedema): 
A. I seek medical attention instantly. 
B. I reduce the dosage of the medication and attempt to expedite the elective appointment with my doctor. 
C. I discontinue the medication and attempt to expedite the elective appointment with my doctor. 
D. I discontinue the medication and wait for the next elective appointment with my doctor. 
E. I discontinue all my medications and wait for the next elective appointment with my doctor.
6. Do you find all your medications necessary for your health? 
A. Yes, I do. 
B. I find most of my medications to be beneficial for my health. 
C. I find only some of my medications to be beneficial for my health. 
D. I find some of my medications to be beneficial for my health, while the others to be harmful for me. 
E. I find the majority of my long-term medications to be harmful for me.
7. Does your doctor inquire about medication-related problems that you might possibly experience? 
A. Yes, on every appointment. 
B. Yes, he/she usually does. 
C. Yes, but only sometimes. 
D. Yes, but only occasionally. 
E. No, never.
8. Do you tell truth when asked by your doctor about medication-related problems? 
A. Yes, always.  
B. Almost always. 
C. I try to be honest, but sometimes it is hard to admit to non-compliance with doctor’s recommendations 
D. Sometimes yes, another time no. 
E. No, I don’t. I find it my own private business.
We also determined the adherence levels based on 
the percentiles. 
Results
Four hundred and thirteen patients with a cardio-
vascular disease were included into the study. The 
mean age was 60.8 ± 9.7 years, and 27.1% of the total 
number (112 of 413) were women. The questionnaires 
were completed anonymously by 401 patients.
Validation of the Adherence Scale in Chronic 
Diseases 
The best known tool used to check the internal 
consistency of a questionnaire is the a- Cronbach coef-
ficient. Therefore, we assessed the internal consistency 
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Table. 2. Correlation coefficients for all 8 items
Item 1 2 3 4 5 6 7
1 1.000 0.112 0.412 0.391 0.311 0.263 0.162
2 0.112 1.000 0.163 0.102 0.182 0.230 0.129
3 0.412 0.163 1.000 0.539 0.404 0.298 0.266
4 0.391 0.102 0.539 1.000 0.401 0.346 0.212
5 0.311 0.182 0.404 0.401 1.000 0.358 0.281
6 0.263 0.230 0.298 0.346 0.358 1.000 0.343
7 0.162 0.129 0.266 0.212 0.281 0.343 1.000
8 0.356 0.084 0.445 0.425 0.337 0.289 0.218
Figure 1. Scree plot
using a-Cronbach coefficient and we obtained the value 
0.739. According to the literature, such result confirmed 
reliability and homogeneity of the questionnaire [10]. 
We also calculated the a-Cronbach coefficient for the 
questionnaire after removing individual questions. The 
a-Cronbach coefficient was higher (0.752) when item 
2 was not used for computation. The coefficient was 
also slightly higher (0.746) when item 7 was excluded 
from computations. We estimated the correlation coef-
ficients between individual items. The analysis showed, 
that item 2 has the lowest correlations with other 
items. The highest correlation coefficient for this item 
was 0.23 (correlation coefficient with item 6). All cor - 
relation coefficients are presented in Table 2.
In the procedure of validation one must verify 
the validity structure and indicate the dimension of 
questionnaire. The presence of multidimensionality is 
connected with the presence of highly correlated group 
of items. We also analyzed the scale in this respect 
using factor analysis. This analysis can generate the 
possible subscales which are represented by sets of 
items within the questionnaire. At first we exanimated 
the assumption of factor analysis for the analyzed data. 
We also assessed: the determinant of correlation matrix, 
Kaiser-Mayer-Olkin (K-M-O) statistic (to measure sam-
pling adequacy) and we conducted the Bartlett’s test 
of sphericity. The determinant of correlation matrix 
was 0.196, the value of K-M-O statistic was 0.847 and 
the Bartlett’s test of sphericity was statistically sig-
nificant. Such results indicated the eligibility of the 
dataset for using factor analysis. The Shapiro-Wilk 
test was not statistically significant, therefore, the 
factor analysis was conducted using principal com-
ponent analysis with Oblimin rotation. We determined 
the components of the questionnaire in line with the 
Kaiser criterion. We obtained two components which 
accounted for about 52% of variance in the dataset. 
Figure 1 shows the scree plot with marked eigenval-
ues for each factor. The scree plot confirmed the choice 
of the two components. 
Table 3 presents the factor loadings for each 
items. One can determine the items which create those 
Table 3. The values of factors loading for the items 1–8
Item Component 1 Component 2
1 0.562 –0.004
2 –0.032 0.339
3 0.755 -0.022
4 0.722 -0.012
5 0.364 0.302
6 0.025 0.679
7 0.048 0.452
8 0.600 0.011
two components. It is recognized that criteria for such 
determination are arbitrary. In the literature it is suggest-
ed that if the value of loading factor is less than 0.4, it 
indicates low factor loadings. In the case of our dataset, 
for the first component, items: 1, 3, 4 and 8 had factors 
loading > 0.4, while for the second component, items 
6 and 7 showed factors loading > 0.4. Items 2 and 5 did 
not have sufficient loading. We denoted the lowest factor 
loading for item 2 (–0.032 for the first component and 
0.339 for the second one).
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We verified the value of the correlation coefficient 
for those two components and it was 0.633. Therefore, 
we concluded that the components are sufficiently 
correlated. In the light of such results we excluded item 
2 from the questionnaire. 
We also conducted the validation procedure again 
for items: 1, 3–8. The a-Cronbach coefficient was higher 
(0.752), which indicated satisfactory internal consisten-
cy. We examined the assumption of factor analysis for 
the new dataset. The determinant of correlation matrix 
was 0.211, the value of K-M-O statistic was 0.848 and 
the Bartlett’s test of sphericity was statistically signif-
icant. We conducted the factor analysis again, using 
principal component analysis with Oblimin rotation. For 
the analyzed data, according to the Kaiser criterion, we 
could extract only one component. 
The exclusion of item 2, which had the lowest cor-
relation coefficient with other items, showed that in fact 
the proposed questionnaire focuses on measurement 
of one coherent target. Now an attempt to extract 
more than one component through factor analysis will 
fail, because even if such components exist, they are 
highly correlated.
Adherence levels
We described a new tool, which can measure the ad-
herence. Every new questionnaire should be associated 
with a scale, which indicates the level of the measured 
effect. In the case of a scale for which the total score 
has normal distribution a sten score can be defined. In 
our dataset we could not do that because of the skewed 
distribution of the total score. Hence, we determined the 
adherence levels based on the percentile scale.
We assumed that the total score higher than 
30 percentiles indicates low adherence, the total score 
between 30 and 70 percentiles indicates medium ad-
herence and the total score higher than 70 percentiles 
indicates high adherence. The described criterion is 
presented in Table 4. In the table we included the ad-
herence levels for the scale with maximum total score 
32 and 28 (after excluding item 2).
We also present the descriptive statistics for the ques-
tionnaire. Table 5 contains the descriptive statistics for the 
original version of the questionnaire and the version without 
item 2. The adherence levels based on the percentile scale 
and the descriptive statistics reveal the effect of negatively 
skewed distribution of the total score. That is why the low 
level of adherence ends at 23 and the high score begins 
at 29. The median is 24, and the minimum score is 9. 
Discussion 
Our study demonstrated a high reliability and crite-
rion-related validity of the Adherence Scale in Chronic 
Table 4. Adherence levels
Maximum Total Score  = 32
Percentile Score Level
10 20 Low
20 23
30 24 Medium
40 25
50 26
60 27
70 28
80 29 High
90 31
Maximum Total Score = 28
Percentiles Score Level
10 18 Low
20 20
30 21 Medium
40 23
50 24
60 25
70 26
80 27 High
Diseases. It is a simple and quick to carry out survey, 
which allows to assess the risk of non-adherence to 
medications used in chronic illnesses treatment. Non-ad-
herence is determined by several factors [5–7]. Our 
survey helps in their identification, especially in identifi-
cation of behaviours associated as well as determinants 
of adherence related to situations and convictions. The 
knowledge of high possibility of non-adherence to the 
recommended therapy by our patient motivates us to 
improve our engagement since some of our patients 
require more attention than the others. The effort put into 
our work with a patient is extremely important and, what 
is more, irreplaceable. It can prevent misunderstanding 
of the recommendation and makes our patients feel im-
portant members of the team engaged in the therapeutic 
process, instead of being passive recipients. 
The presented questionnaire is accurate and con-
sistent. However, the performed analyses have demon-
strated that second question regarding financial aspects 
of the treatment lowers the consistency of the test and 
therefore needs to be modified or excluded. This item 
was the only one in the survey raising financial issues 
and its detachment from the other questions is not sur-
prising. Moreover, financial aspect of the treatment is 
a very important issue in all populations [11] and it might 
have an impact on responders’ answers. In our further 
studies we plan to modify this question appropriately, 
thereby increasing the consistency of the questionnaire.
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Table 5. Descriptive statistics for the questionnaire
Item Mean Std Median Min Max Q1 Q3
1 3.55 0.59 4.00 1.00 4.00 3.00 4.00
2 2.67 0.86 3.00 0.00 4.00 2.00 3.00
3 3.47 0.74 4.00 1.00 4.00 3.00 4.00
4 3.60 0.73 4.00 0.00 4.00 3.00 4.00
5 3.37 0.85 4.00 0.00 4.00 3.00 4.00
6 3.31 0.85 3.00 0.00 4.00 3.00 4.00
7 2.20 1.26 2.00 0.00 4.00 1.00 3.00
8 3.55 0.72 4.00 0.00 4.00 3.00 4.00
Total score 
(1–8)
25.72 4.04 26.00 11.00 32.00 23.00 29.00
Total score 
(1.3–8)
23.05 3.76 24.00 9.00 28.00 21.00 26.00
Limitations of the study
Several limitations of our study need to be ac-
knowledged. The main limitation is that our study 
was conducted in a single medical centre. Further, 
the study population was small, and the survey must 
be conducted in a larger population of patients with 
chronic illnesses. The questionnaire was performed 
anonymously and in the future patient characteristic 
must be included in the analysis. Moreover, we did not 
compare our survey results with an objective method 
of adherence measurement such as: National Health 
Found reports, electronic monitoring, drug concentra-
tion in blood, etc. The survey was not compared with 
any other questionnaires. In the future studies, com-
parison of the Adherence Scale in Chronic Diseases 
with the most often used 8-item Morisky Medication 
Adherence Scale should be included.
Conclusion 
The Adherence Scale in Chronic Diseases is a practi-
cal, reliable, consistent and well validated instrument for 
identifying specific obstacles to medication adherence. 
Its simplicity causes that it can be successfully applied 
in daily practice by health care professionals. Our survey 
has the potential to improve patient — health care profes-
sional communication and relationship, which are the key 
points providing higher adherence to the specific therapy. 
Future studies are required to assess the actual connec-
tion between the Adherence in Chronic Diseases Scale 
and the adherence measured with objective methods.
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